Pharma / Biotech

Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer.




Icon for Wiley Related Articles

Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer.

J Biomed Mater Res A. 2019 09;107(9):1933-1944

Authors: Jain A, Mahira S, Majoral JP, Bryszewska M, Khan W, Ionov M

Abstract
Irresponsiveness of triple negative breast cancer (TNBC) toward conventional therapies has drawn attention toward siRNA therapeutics. In gene delivery, dendrimers are gaining significant attention due to their characteristic features and polo-like kinase (PLK1) is reported as a potential target for TNBC. In this work, phosphorus and polyamidoamine dendrimer (generation 3 and 4 of each type) are explored to address delivery challenges of PLK1 siRNA (siPLK1). Dendriplexes were formed and complexation was found at 3:1 N/P ratio for all dendrimers by gel electrophoresis. Complexation was also supported by zeta potential, circular dichroism and intercalation assay. Dendriplexes were found to be stable in presence of ribonuclease and serum. Dendriplexes resulted in enhanced cell uptake of siPLK1 compared to siPLK1 solution in MDA-MB-231 and MCF-7 cells. Dendriplexes caused increased cell arrest in sub-G1 phase compared to solution. These observations suggested phosphorus and polyamidoamine dendrimers as potential carriers for siPLK1 delivery to treat TNBC.

PMID: 31008565 [PubMed - indexed for MEDLINE]

Source link








Related posts

QUIP (Sodium Monofluorophosphate) Paste, Dentifrice [Quip NYC Inc.]

Newsemia

AMMI NICOTIANA ADULT SIZE Suppository [Uriel Pharmacy Inc.]

Newsemia

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours.

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy